Endometrial cancer research spans molecular classification, immunotherapy in mismatch repair-deficient disease, and antibody-drug conjugates in recurrent settings.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A single-center, non-randomized phase 2 basket trial tested ado-trastuzumab emtansine (T-DM1) across five disease-specific cohorts of HER2-amplified solid tumors, asking whether a shared molecular driver predicts benefit from a HER2-targeted antibody-drug conjugate regardless of tumor origin.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
A single-center, investigator-initiated Phase II trial using a Simon two-stage design tested sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, in 50 evaluable patients with recurrent or persistent endometrial cancer who had progressed after platinum-based chemotherapy, enrolled between March 2020 and December 2024.